Cancer

Liquid Biopsy Is an Early Cancer Screening Breakthrough Technology

Liquid biopsy is a groundbreaking, non-invasive method for early cancer detection and monitoring, offering significant clinical potential.

Cancer

KRAS ctDNA Is Predictor of Metastasis and Survival in Pancreatic Cancer

A Mayo Clinic study found that detecting KRAS ctDNA in pancreatic cancer patients signals a higher risk of cancer spread and poorer survival.

Cancer

ExRNA Plays a Role in Head and Neck Cancers

A study highlights the role of exRNA in head and neck cancers (HNCs), emphasizing their potential as non-invasive biomarkers for diagnosis.

Why Self-collection Is the Means to Maximize Cervical Cancer Screening

Jan 31, 2025 | Cervical (HPV)

There are significant barriers to cervical cancer screening. Sample self-collection promises to improve access to testing and treatment.

Urine Test Detects Prostate Cancer and Reduces Unnecessary Biopsies

Jan 29, 2025 | Prostate, Urinalysis & Toxicology

A new study validated a urine test that offers a less invasive, more accurate alternative to traditional prostate cancer screening.

Novel Lab-on-Chip Platform Aims to Expedite Cancer Diagnoses

Jan 28, 2025 | Cancer

A new lab-on-chip platform uses standing surface acoustic waves and AI to separate CTCs from red blood cells for earlier cancer diagnosis.

Datar Cancer Genetics Unveils AI-Driven Video-Based Chemotherapy Testing

Jan 28, 2025 | Cancer

The video-reporting service for in-vitro chemosensitivity testing uses real-time visual evidence to assess chemotherapy drug effectiveness.

Leptomeningeal Disease Diagnosis in Diffuse Midline Gliomas Achieved via ctDNA Detection

Jan 27, 2025 | Unknown Origin & Other Cancer Types

Researchers diagnosed leptomeningeal disease in diffuse midline gliomas by detecting H3K27M-mutant ctDNA from cerebrospinal fluid.

OGT Launches Myeloid MRD Panel for Sensitive AML Biomarker Detection

Jan 23, 2025 | Leukemia, Sequencing Systems

OGT’s SureSeq Myeloid MRD Panel offers a NGS solution for ultra-sensitive detection of MRD biomarkers in acute myeloid leukemia.

New Biomarker Algorithm for Noninvasive Detection of Esophageal Cancer

Jan 22, 2025 | Unknown Origin & Other Cancer Types

A biomarker-based algorithm combined with a noninvasive test identifies those at risk for esophageal cancer or precancerous conditions.

Why Genomic Tests for Prostate Cancer Need Better Data

Jan 21, 2025 | Prostate

A review found gaps remain for genomic classifier tests for their cost-effectiveness, clinical utility, and impact on diverse populations.

Home Test Kit Detects Bladder Cancer with 88.8% Accuracy

Jan 21, 2025 | Unknown Origin & Other Cancer Types, Urinalysis & Toxicology

Researchers developed a urine-based diagnostic kit for bladder cancer, offering a solution for early detection and monitoring at home.

BD HPV Assay Added to ASCCP Guidelines for Cervical Cancer Screening

Jan 16, 2025 | Cervical (HPV)

BD’s HPV Assay has been added to the ASCCP Risk-Based Management Guidelines, leveraging extended genotyping for enhanced HPV screening.

Roche Gets FDA Clearance for Highly Sensitive B-cell Lymphoma Test

Jan 16, 2025 | Lymphoma

A new test for Roche received FDA clearance as a sensitive diagnostic tool to differentiate B-cell lymphomas for improved diagnosis.

NCCN Guidelines Add ctDNA-MRD Testing Recommendation for B-Cell Lymphoma

Jan 16, 2025 | Lymphoma, Molecular Diagnostics

Foresight Diagnostics’ ctDNA-MRD testing has been included in the NCCN Clinical Practice Guidelines for diffuse large B-cell lymphoma.

Risk of Lung Cancer Recurrence Linked to ctDNA Levels

Jan 15, 2025 | Lung Cancer, Molecular Diagnostics

A new demonstrates the high sensitivity of the NeXT Personal test for detecting ctDNA in early-stage lung cancer.

New Liquid Biopsy Test Offers Early Detection of Multiple Cancers

Jan 13, 2025 | Cancer

The liquid biopsy test uses advanced DNA analysis and machine learning to detect six cancers at early stages with high sensitivity.

Naveris Expands Availability of Test in Anal Cancer MRD Surveillance

Jan 13, 2025 | Cervical (HPV)

Naveris expanded the commercial availability of its NavDx test, a non-invasive tool for detecting MRD in HPV-positive anal cancer patients.

Category: Cancer

Cancer

Cancer

Cancer